Background: A routine audit revealed that the analytical method used to measure digoxin
Introduction:
Digoxin is still used in the treatment of atrial fibrillation (AF) and heart failure but requires therapeutic drug monitoring (TDM) due to its narrow therapeutic range (0.8-2.0 µg/L for AF). 1, 2 TDM requires a complex set of people and system resources -pre validation and calibration, analytical aspects, post validation, reporting and interpretation; a set of factors not commonly found all together in one laboratory.
There is evidence to show that measured plasma digoxin concentrations may vary by a clinically significant amount as a result of the use of different methods and/or analysers and from interference from digoxin-like immunoreactive substances (DLIS). [3] [4] [5] [6] [7] This can lead to inappropriate digoxin dosing which can potentially lead to serious problems for patients' health. 3, 4 During an external quality assurance program in 2010, the Beckman Coulter plasma and serum This would seem clinically significant as higher concentrations of digoxin have been associated with an increase in toxicity. 8, 9 A
C C E P T E D
The present study considered whether clinicians made decisions based on the patient's clinical situation or impression and not solely on measured digoxin concentrations. If clinicians based their decisions solely on the clinical impression, then any discordance between measured digoxin concentrations may not have had a significant clinical impact.
A literature review concluded that there are no data on the clinical outcomes of either biased or imprecise plasma digoxin concentration measurements regardless of the cause; whether from variability between analysers or interference from DLIS. [4] [5] [6] [7] However, a New Zealand study has
shown that clinicians were more inclined to dose patients based on their clinical situation when serum digoxin concentrations were low, while high digoxin concentrations were deemed to represent toxicity regardless of the patient's clinical impression. 10 This is consistent with research showing that higher digoxin concentrations may correlate with digoxin toxicity. 8, 9 Nonetheless, data on current digoxin prescribing in Australia are still lacking; and it has been suggested by the literature that future method comparison studies would benefit from protocols that include the effect on clinical decision-making, not solely measures of analytical performance in isolation. 4 Consequently, this is a pilot study to describe the prescribing behaviour around out of range digoxin concentrations, and to assess if miscalibrated digoxin immunoassays contribute to clinically relevant effects.
Thus, the aims of this study were to firstly ascertain if recalculation of data collected during 
Patient selection for clinical relevance section:
As this was a pilot study, a smaller sample was chosen for an in depth chart review. 50 charts from the Princess Alexandra Hospital (PAH) of patients who had borderline digoxin concentrations (0.8 or 2.0 µg/L) or were outside of the range (< 0.8 or >2.0 µg/L) during a 6 month period in 2009 were randomly selected by systematic sampling using an equalprobability method. Of these 50 charts, 25 charts had borderline digoxin concentrations with 7 A C C E P T E D charts in the >2.0 µg/L group and 18 charts in the < 0.8 µg/L group. The other 25 charts had digoxin concentrations outside of the range with 12 charts in the >2.0 µg/L group and 13 charts in the < 0.8 µg/L group. Ten additional charts of patients who had digoxin concentrations within the range were also randomly selected using the same methodology. These ten charts were used as control samples as it was assumed that no changes in dosing were made if concentrations were within the range.
Thus, including controls, 60 charts in total were examined. Charts were excluded if insufficient clinical data were available to make a judgement on whether appropriate management was undertaken; or if the patient was on digoxin for indications other than AF. Patients who were on digoxin for both AF and congestive heart failure were included.
All concentrations were measured using the Beckman DxC (Beckman Coulter, Brea, CA)
analyser at the PAH, Queensland, Australia. Patient data collected included age, sex, sampling and dosing times, digoxin concentrations and doses, serum creatinine, serum potassium, weight, co-morbidities, number of medications, signs of under or overdosing and whether patients were concurrently on other anti-arrhythmic drugs. Sampling and dosing times were recorded to ensure digoxin concentrations were sampled at the appropriate times ( Table 1) . Although creatinine clearance estimations would have been a better estimate of renal function, serum creatinine was used due to the inability to locate patients' weights in more than half of the charts. The list of recorded data is further detailed in Table 1 .
Study end-points:

Clinical implications of underestimating digoxin concentrations
The second aim of this study was to assess whether unnecessary alterations in digoxin doses would have occurred after recalculating the data collected in 2009 to the corrected concentrations. Thus, clinical charts were examined to assess whether appropriate decisions were made based on the original concentrations prior to instrument recalibration in 2009.
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Decisions for that particular concentration were classified as either: appropriate or
inappropriate.
An appropriate decision was defined as a change in digoxin dose consistent with the corrected concentration and was the variable of interest. For example, if the corrected concentration was below the range and an increase in dose was recorded, this would be an appropriate decision.
However, if the corrected concentration fell below the range and no change in dose was recorded, this would be defined as an inappropriate decision for the purpose of this study. Here, the clinical stability of the patient was not taken into account; only if the corrected concentration warranted a change in dose in the view of the independent expert reviewer.
Concentrations that were borderline and outside the range were compared to concentrations that were within the range (control) using Fisher's exact tests. Subgroup analysis was also performed comparing whether the difference between appropriate decisions varied between the < 0.8, 0.8, 2.0 and > 2.0 µg/L groups.
Clinical prescribing behaviour for digoxin
The third aim was to elucidate whether clinicians tended to dose digoxin based on the measured digoxin concentration or based on a patient's overall clinical impression. This was of interest as there are currently no digoxin prescribing guidelines available at the PAH. Actions for each digoxin concentration selected were classified into 2 groups: actions based on either concentration or clinical impression. It was agreed that if a clinician used both the patient's concentration and the clinical impression of the patient, this would be classified under the clinical impression group. This is because it was difficult to ascertain whether concentrations that were out of the range happened coincidently when clinicians altered the dose of patients.
The definitions for the two groups are as follows:
Concentration only: Dose changed after concentration selected was out of the therapeutic range without any signs of clinical instability. 
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Results:
Difference between pre and post recalculated digoxin concentrations 
Clinical implications of underestimating digoxin concentrations
57 charts in total were examined. Three charts were excluded from the borderline group according to the exclusion criteria. The final number of charts examined per group is summarised in Table 2 .
Of the 47 charts examined of patients with concentrations measured in 2009 that were borderline or out of the range, 34 (72.34%) charts had appropriate decisions. There was no significant difference when compared to the controls which had 100% appropriate decisions (P = 0.10). Subgroup analysis was also performed comparing whether the difference between appropriate decisions varied between the < 0.8, 0.8, 2.0 and > 2.0 µg/L groups. There was a significant difference between the < 0.8 µg/L group and the other three groups (0.8 µg/L: P=0.0003, 2.0 µg/L: P=0.016, > 2.0 µg/L: P=0.009). This was because post recalculated concentrations that were < 0.8 µg/L were still below the range but no increase in doses were noted in the majority of these patients. There were no significant changes between the other groups.
Clinical prescribing behaviour of digoxin
Of the 47 charts examined of patients with concentrations that were borderline or out of the range, the majority of decisions were based on clinical impression (85.1%) as opposed to concentration alone (14.9%). However, this was not equal in all groups. Decisions made by concentration only were significant for digoxin concentrations > 2.0 µg/L compared to other There appeared to be a trend for clinical impression decision making for patients that were on other anti-arrhythmic drugs (OR 3.06, 95% CI 0.53-17.66), however this proved to be not significant (P=0.24). Other variables also did not appear to significantly impact on whether clinicians based their decision on the clinical impression or the digoxin concentration as demonstrated in Table 3 . The impact of serum potassium was not analysed as all samples recorded were within the appropriate reference range. 
Clinical implications of underestimating digoxin concentrations
Overall, recalibration of the digoxin assay did not significantly clinically impact on unnecessary decision making. However, there was a significant difference between the < 0.8 µg/L group and the other three groups. This was because post recalculation, concentrations that were < 0.8 µg/L were still below the range but no increases in doses were noted in the majority of them.
Clinicians are generally satisfied with a concentration that is below the therapeutic range as long as the patient is clinically stable (as discussed below). One clinician wrote that, "There was no need for repeat digoxin concentrations as the aim for treatment is rate control and the concentrations do not need to be therapeutic". In another chart of a patient with concomitant
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congestive heart failure the clinician wrote that "it was appropriate to aim for low concentrations in congestive heart failure"; a clinical practice which is in fact supported by the literature but for which there is no quoted therapeutic range.
12-14
Clinical prescribing behaviour of digoxin
The vast majority of decisions when prescribing digoxin were based on the clinical impression as opposed to concentration alone. This was particularly true with concentrations that were below the therapeutic range even when concentrations were very low (0.3 µg/L). However changes based on concentrations were significantly higher in the > 2.0 µg/L group as clinicians appear to be more cautious about toxicity at concentrations above the range. In fact, in charts of two patients who were borderline high (2.0 µg/L), clinicians specifically noted that although the patients were rate controlled, the dose was reduced because the digoxin concentration was close to the upper limit. A possible contributing factor to this finding is the fact that Pathology
Queensland has assigned a digoxin concentration of > 2.0 µg/L as a critical result that must be verbally given to the treating team of the patient, thus, giving the treating clinician an additional prompt for action. Nonetheless, although digoxin concentrations may not always correlate well to the clinical impression 10 , this trend in dosing is probably associated with best clinical practice. This is because digoxin toxicity could potentially be fatal and the clinical benefits of higher concentrations are questionable. 10 These findings of clinicians having a greater reliance on laboratory results when digoxin concentrations are at or above the upper limit of the therapeutic range demonstrate similarities in prescribing practice between Australia and New Zealand.
10
It was also noted that there was a trend towards more decisions being based on the clinical impression rather than on digoxin concentrations for patients who were on other anti-arrhythmic drugs; however, this was not significant. This trend may be explained by the fact that doses of other co-administered anti-arrhythmic drugs were changed concomitantly, while the digoxin dose was unaltered regardless of the concentration measured. Other variables did not appear to
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have any significant impact on whether clinicians based their decisions on the clinical picture, clinical impression, or concentration ( Table 3) .
It can thus be concluded that clinicians generally dosed digoxin based on a patient's clinical impression when concentrations were < 0.8 µg/L. Conversely, they tended to use both the patient's clinical impression and digoxin concentrations for concentrations > 2.0 µg/L. Overall however, the majority of clinicians were treating the patient and not the concentration on a test report, even when the concentrations were well outside the 'therapeutic range'. Whether the heavy reliance on the clinical impression is a result, at least in part, of a clinician's awareness of the limitations in assay method accuracy or due to influence from local prescribing culture needs to be further investigated. Additionally, it can be implied that perhaps the current prescribing trends may be adequate as improved assay accuracy and performance could possibly result in the increased reliance on TDM.
The fact that clinicians were treating 'the patient and not the concentration,' is a reassuring outcome. It suggests that although biases in digoxin assay methods are important to be aware of, inappropriate changes in dosing are unlikely to occur. In particular, increases in the number of digoxin toxicities are unlikely to occur because although clinicians generally dosed the patient according to the clinical impression when digoxin concentrations were low or within the range, they were guided more emphatically by concentrations when above the range. Given the use of low digoxin concentrations to good effect clinically, perhaps the lower limit of the current therapeutic range (0.8 µg/L) needs to be re-evaluated.
Lastly, this pilot study demonstrates current digoxin prescribing trends in a large Australian tertiary hospital and the clinical use of digoxin concentrations. This could guide future studies containing protocols that include the effects on clinical decision-making from discordant drug concentration results from recalibration or altering methods. Furthermore, the study protocol 
Conclusion
Although it has been demonstrated that recalculating digoxin concentrations measured in 2009
to their 'corrected' values produced a significant change in concentrations and values 'inside'
and 'outside' of the therapeutic range, this does not appear to have had an influence on patient treatment; at least in the eight to ten percent bias range. Our chart analysis study has shown that the majority of clinicians used their clinical impression to dose digoxin, rather than concentration for most patients, with greater reliance on the concentration at or above the upper limit of the therapeutic range. Whilst unexpected, it is a clinically useful finding and consistent with TDM teaching i.e. that a result be used in the total context of the patient's clinical impression when prescribing a dose of a drug. This work and the study design are likely to be helpful for laboratories when planning research to assess clinical impact when a new instrument or methodology is introduced in the laboratory.
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